1-20 of 33 results for subject:"Medical equipment"
Librarians' tools
- Search time
- 0.239 seconds
- Solr query time
- 0.006 seconds
- Search query
- subject:"Medical equipment"
- We searched for
- subject_t:"Medical equipment" OR subject_t:"Medical devices" OR subject_ses:91970
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Business and Trade, what assessment his Department has made of the adequacy of the length of the statute of limitations for medical devices as specified under the Consumer Protection Act 1987.
To ask the Secretary of State for Business and Trade, what assessment his Department has made of the adequacy of the length of the statute of limitations for medical devices as specified under the Consumer Protection Act 1987.
Given the importance, breadth and complexity of this area of law – and as I set out in Committee on the Product Regulation and Metrology Act – the Government has asked the Law Commission to conduct a full review of product liability legislation. This includes considering the time limits for bringing claims. Following a wide consultation that will begin soon, I expect the Law Commission to make recommendations later next year.
To ask the Secretary of State for Business and Trade, if he will make an assessment of the potential merits of amending the Consumer Rights Act 2015 to increase statute of limitations to 20 years for faulty medical devices.
To ask the Secretary of State for Business and Trade, if he will make an assessment of the potential merits of amending the Consumer Rights Act 2015 to increase statute of limitations to 20 years for faulty medical devices.
The Consumer Protection Act, which contains our product liability legislation, has been in place since 1987 and my department is indeed undertaking a review of it, during which we will consider all aspects, including those claim limits my Honourable friend mentions. Following this review, should we believe changes are needed, we will bring forward the necessary primary legislation to ensure our laws remain up to date and fit for the future.
To ask the Secretary of State for Health and Social Care, what criteria his Department applied in the decision making process for the automatic approval extension of lateral flow tests, previously approved until 4 February 2022.
To ask the Secretary of State for Health and Social Care, what criteria his Department applied in the decision making process for the automatic approval extension of lateral flow tests, previously approved until 4 February 2022.
Tests with a current Coronavirus Test Device Approvals application have been allowed to remain on the market until 28 February 2022 or until their application is determined. This was permitted to avoid a serious public health risk during a period of high demand and where the tests had successfully undergone validation by a public sector body.
To ask the Secretary of State for Health and Social Care, when the CTDA approval process for Lateral Flow Tests will be concluded.
To ask the Secretary of State for Health and Social Care, when the CTDA approval process for Lateral Flow Tests will be concluded.
The CTDA approval process is an ongoing regulatory regime. There is no current end date and new applications for approval may be made at any time.
New clause 44 (Directors of public health) debated and withdrawn. New clause 45 (Duty on integrated care boards to have regard to net zero commitment) debated and withdrawn. New clause 46 (Exclusion of NHS bodies from ability to withhold information requested under the Freedom of Information Act 2000 on commercial grounds) debated and withdrawn. New clause 49 (Protection of the title of "nurse") debated and withdrawn. New clause 50 (Access to innovative medicines and medicinal products review) debated and withdrawn. New clause 51 (Duty on integrated care partnerships to prepare and deliver a Best Start for Life strategy) debated and withdrawn. New clause 52 (Plan for implementing recommendations of the Independent Medicines and Medical Devices review) negatived on division (6 to 7). New clause 53 (Women’s representation in reproductive healthcare planning) debated and withdrawn. New clause 54 (Enhanced data collection) debated and withdrawn. New clause 56 (Domestic violence training for GPs) debated and withdrawn. New clause 57 (Cancer strategy) debated and withdrawn.
New clause 44 (Directors of public health) debated and withdrawn. New clause 45 (Duty on integrated care boards to have regard to net zero commitment) debated and withdrawn. New clause 46 (Exclusion of NHS bodies from ability to withhold information requested under the Freedom of Information Act 2000 on commercial...
It is a pleasure to see you in the Chair this afternoon, Mr Mundell. I want to add my congratulations to those offered to the hon. Member for Strangford (Jim Shannon), on securing the debate and on his persistence in getting it almost a year after he first requested it....
It is a pleasure to see you in the Chair this afternoon, Mr Mundell. I want to add my congratulations to those offered to the hon. Member for Strangford (Jim Shannon), on securing the debate and on his persistence in getting it almost a year after he first requested it....
To ask the Secretary of State for Health and Social Care, what proportion of the proposed 100,000 tests per day for covid-19 will be (a) antigen and (b) antibody tests.
To ask the Secretary of State for Health and Social Care, what proportion of the proposed 100,000 tests per day for covid-19 will be (a) antigen and (b) antibody tests.
The Government announced it had achieved its target to deliver 100,000 tests per day on 1 May 2020, with over 122,000 tests delivered on 30 April 2020.
All tests currently being used to diagnose COVID-19 are Polymerase Chain Reaction (PCR) swab tests using swabs taken from the nose and throat. These confirm when people currently have COVID-19.
To ask the Secretary of State for Health and Social Care, how many swabs were held in the pandemic stockpile on 31 December in each the last 10 years.
To ask the Secretary of State for Health and Social Care, how many swabs were held in the pandemic stockpile on 31 December in each the last 10 years.
The Department’s advisory Committee for New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) makes recommendations to the Government on what medicines and clinical consumables should be stockpiled for pandemic influenza preparedness including relevant scientific information that is used for estimating target stock levels.
NERVTAG has recommended the stockpiling of (amongst other products) FFP3 respirators, eye protection, aprons and gloves. Data on the number of respirator masks, eye protection, aprons and gloves are not published in the format requested.
Surgical gowns are not currently part of the pandemic stockpile. Public Health England is currently implementing a commission to add these items to the stockpile.
There are no recommendations from NERVTAG to stockpile swabs.
To ask the Secretary of State for Health and Social Care, what estimate he has made of when an antibody test for covid-19 will become available; and what plans he has for the roll-out of that test.
To ask the Secretary of State for Health and Social Care, what estimate he has made of when an antibody test for covid-19 will become available; and what plans he has for the roll-out of that test.
Confidence in antibody test needs to be established before being rolled out as part of a national programme of testing. The COVID Scientific Advisory Panel, led by Professor Sir John Bell has established a rapid evaluation process to establish the reliability of antibody tests. The results from the first evaluation of commercial antibody tests have shown that, of the tests the Government has looked at so far, none have proven accurate enough to be rolled out for public use.
To ask the Secretary of State for Health and Social Care, whether the Government has plans to implement EU regulatory changes in respect of in vitro diagnostic medical devices regulation; and if he will make a statement.
To ask the Secretary of State for Health and Social Care, whether the Government has plans to implement EU regulatory changes in respect of in vitro diagnostic medical devices regulation; and if he will make a statement.
The United Kingdom has left the European Union and entered a transition period from 1 February to 31 December 2020. During this period the Government will forge new partnerships with the EU and the rest of world.
Both the EU and the UK are committed to agreeing a future partnership by the end of 2020 and are working to achieve this. The UK will continue to ensure fast access to devices for patients and maintain high standards of patient safety.
To ask the Secretary of State for Health and Social Care, what the Government's policy is on the (a) recognition and (b) enforcement of CE Marking requirements for (i) medical devices and (ii) in vitro diagnostics; whether the Government has plans to implement the in vitro diagnostic medical devices regulation;...
To ask the Secretary of State for Health and Social Care, what the Government's policy is on the (a) recognition and (b) enforcement of CE Marking requirements for (i) medical devices and (ii) in vitro diagnostics; whether the Government has plans to implement the in vitro diagnostic medical devices regulation;...
The United Kingdom has left the European Union and entered a transition period from 1 February to 31 December 2020. During this period the Government will forge new partnerships with the EU and the rest of world.
Both the EU and the UK are committed to agreeing a future partnership by the end of 2020 and are working to achieve this. The UK will continue to ensure fast access to devices for patients and maintain high standards of patient safety.
Motion to consider.
Motion to consider.
To ask the Secretary of State for Health and Social Care, how many patients took receipt of an insulin pump in each region of England in each of the last three years.
To ask the Secretary of State for Health and Social Care, how many patients took receipt of an insulin pump in each region of England in each of the last three years.
Information is available on the number of people in England who are recorded as being on an insulin pump in the National Diabetes Audit (NDA) 2016-17, by NHS England Region and year started on the pump and can be found in the following table.
NHS England Region | NHS England Region Name | 2014 | 2015 | 2016 |
Q71 | London | 165 | 200 | 175 |
Q72 | North (Yorkshire And Humber) | 80 | 105 | 130 |
Q74 | North (Cumbria And North East) | 140 | 110 | 105 |
Q75 | North (Cheshire And Merseyside) | 20 | 35 | 35 |
Q76 | Midlands And East (North Midlands) | 45 | 55 | 35 |
Q77 | Midlands And East (West Midlands) | 50 | 60 | 25 |
Q78 | Midlands And East (Central Midlands) | 75 | 70 | 70 |
Q79 | Midlands And East (East) | 105 | 110 | 100 |
Q83 | North (Greater Manchester) | 75 | 60 | 55 |
Q84 | North (Lancashire And South Cumbria) | 25 | 25 | 35 |
Q85 | South West (South West South) | 30 | 45 | 35 |
Q86 | South West (South West North) | 20 | 30 | 25 |
Q87 | South East (Hampshire, Isle Of Wight And Thames Valley) | 15 | 50 | 40 |
Q88 | South East (Kent, Surrey And Sussex) | 90 | 60 | 85 |
Notes:
- The NDA does not hold comprehensive data on all children with diabetes.
- Latest National Health Service trusts and sites file (etrust) can be found at the following link:
https://digital.nhs.uk/services/organisation-data-service/data-downloads/other-nhs-organisations
Not all NHS England Regions are represented in the data, as there were no specialist diabetes services from those regions that participated in the NDA 2016-17.
- Figures are based on people who appear in the 2016-17 NDA who are recorded as having started on an insulin pump in a calendar year between 2014 and 2016.
- Disclosure control has been applied to all figures, as per the NDA publication - all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’.
- The NDA does not have insulin pump data from all specialist services.
- We do not know the year that every person in the collection started on pump therapy (known for 92% of people).
It is a pleasure to serve under your chairmanship, Mr Davies. I join other Members who have expressed their remembrance and condolences to the families of those who died last year, particularly PC Keith Palmer. There was a very moving service in Westminster Hall this morning, which I think was...
It is a pleasure to serve under your chairmanship, Mr Davies. I join other Members who have expressed their remembrance and condolences to the families of those who died last year, particularly PC Keith Palmer. There was a very moving service in Westminster Hall this morning, which I think was...
That is slightly outside my brief, but I understand the intention behind the question and hope that we will be able to come back on it positively.
There are concerns about the risks to patient care. Will the Minister set out how he expects us to address those?
The free movement of...
That is slightly outside my brief, but I understand the intention behind the question and hope that we will be able to come back on it positively.
There are concerns about the risks to patient care. Will the Minister set out how he expects us to address those?
The free movement of...
Motion that this House has considered the effect on the NHS of the UK leaving the EU. Agreed to on question. Sitting adjourned without Question put.
Motion that this House has considered the effect on the NHS of the UK leaving the EU. Agreed to on question. Sitting adjourned without Question put.
To ask the Secretary of State for Health, what proportion of patients who were given an Essure implant were readmitted for follow-up surgery.
To ask the Secretary of State for Health, what proportion of patients who were given an Essure implant were readmitted for follow-up surgery.
This information is not collected centrally.
To ask the Secretary of State for Health, if he will estimate the cost to the NHS of follow-up surgery for patients who have been given an Essure implant.
To ask the Secretary of State for Health, if he will estimate the cost to the NHS of follow-up surgery for patients who have been given an Essure implant.
This information is not collected centrally.
To ask the Secretary of State for Health, how many women have reported problems to the Medicines and Healthcare Products Regulatory Agency about the Essure implant in the last five years.
To ask the Secretary of State for Health, how many women have reported problems to the Medicines and Healthcare Products Regulatory Agency about the Essure implant in the last five years.
Following the suspension of the CE certificate for Essure devices, the manufacturer has agreed to voluntarily quarantine Essure stock in the United Kingdom. Patient safety is our highest priority and we encourage the reporting of any adverse incidents to the Medicines and Healthcare products Regulatory Agency (MHRA), regardless of how long ago the implant was inserted. The MHRA are bound by UK and European Union legislation that preclude us from releasing the information that has been requested. However, there is currently no evidence to suggest any increased risk to patient safety. Any women with questions should speak to their general practitioner or healthcare professional.
I rise to speak to new clause 1, which stands in my name; to amendment 8, which is in the name of my hon. Friend the Member for Burnley (Julie Cooper); and to the other amendments in the group. The Opposition do not oppose the Bill. Our proposals are a...
I rise to speak to new clause 1, which stands in my name; to amendment 8, which is in the name of my hon. Friend the Member for Burnley (Julie Cooper); and to the other amendments in the group. The Opposition do not oppose the Bill. Our proposals are a...